Cogent Biosciences Inc (NASDAQ: COGT)’s stock price has soared by 1.83 in relation to previous closing price of 8.47. Nevertheless, the company has seen a gain of 5.18% in its stock price over the last five trading days. seekingalpha.com reported 2025-01-22 that Small biotech stocks have struggled recently, with the SPDR® S&P Biotech ETF down over 15% in the past ten weeks. The pullback has presented significantly lower entry points on myriad small and mid-cap biotech and biopharma stocks. Today, we look at three of these names that have seen notable recent purchases from insiders and/or beneficial owners.
Is It Worth Investing in Cogent Biosciences Inc (NASDAQ: COGT) Right Now?
The 36-month beta value for COGT is at 1.76. Analysts have varying views on the stock, with 5 analysts rating it as a “buy,” 3 rating it as “overweight,” 3 as “hold,” and 0 as “sell.”
The public float for COGT is 88.88M, and currently, shorts hold a 10.52% of that float. The average trading volume for COGT on January 28, 2025 was 1.58M shares.
COGT’s Market Performance
The stock of Cogent Biosciences Inc (COGT) has seen a 5.18% increase in the past week, with a 9.73% rise in the past month, and a -28.18% fall in the past quarter. The volatility ratio for the week is 7.41%, and the volatility levels for the past 30 days are at 6.59% for COGT. The simple moving average for the past 20 days is 7.05% for COGT’s stock, with a -5.34% simple moving average for the past 200 days.
Analysts’ Opinion of COGT
Robert W. Baird, on the other hand, stated in their research note that they expect to see COGT reach a price target of $8, previously predicting the price at $14. The rating they have provided for COGT stocks is “Neutral” according to the report published on February 26th, 2024.
Citigroup gave a rating of “Buy” to COGT, setting the target price at $11 in the report published on February 08th of the previous year.
COGT Trading at 0.96% from the 50-Day Moving Average
After a stumble in the market that brought COGT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -31.60% of loss for the given period.
Volatility was left at 6.59%, however, over the last 30 days, the volatility rate increased by 7.41%, as shares surge +6.16% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -19.51% lower at present.
During the last 5 trading sessions, COGT rose by +1.89%, which changed the moving average for the period of 200-days by +25.64% in comparison to the 20-day moving average, which settled at $8.04. In addition, Cogent Biosciences Inc saw 10.58% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at COGT starting from Pinnow Cole, who purchase 43,750 shares at the price of $7.60 back on Jan 14 ’25. After this action, Pinnow Cole now owns 45,848 shares of Cogent Biosciences Inc, valued at $332,412 using the latest closing price.
Stock Fundamentals for COGT
Current profitability levels for the company are sitting at:
- -46.61 for the present operating margin
- 0.47 for the gross margin
The net margin for Cogent Biosciences Inc stands at -43.36. The total capital return value is set at -0.79. Equity return is now at value -78.47, with -65.53 for asset returns.
Based on Cogent Biosciences Inc (COGT), the company’s capital structure generated 0.05 points at debt to capital in total, while cash flow to debt ratio is standing at -10.73. The debt to equity ratio resting at 0.06. The interest coverage ratio of the stock is -56.01.
Currently, EBITDA for the company is -205.86 million with net debt to EBITDA at 0.31. When we switch over and look at the enterprise to sales, we see a ratio of 159.78. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.44.
Conclusion
In conclusion, Cogent Biosciences Inc (COGT) has had a better performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
